Skip to content
OpenCapital
Get started

Collegium Pharmaceutical, Inc. COLL Symproic — Product revenues, net

Other product segments

Belbuca
$52.65M+1.9%
Xtampza ER
$50.77M—
Jornay PM
$38.89M+36.3%
Nucynta IR
$26.08M-4.9%
Nucynta ER
$18.23M-7.4%
Symproic and other
$14.45M—
Nucynta ER AG
$1.45M—
Nucynta IR AG
$1.26M—

Similar metrics at other companies

XER
XERSProduct revenue, net — Product revenue, net
$82.45M+42.6%
Vertex Pharmaceuticals logo
VRTXProduct revenues, net — Product revenues, net
$2.99B+8.2%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%
Esperion Therapeutics logo
ESPRProduct sales, net — Total Revenues
$43.4M+24.3%
Aurinia Pharmaceuticals logo
AUPHNet product sales — Revenue
$73.56M+22.7%

Other financials

Income statement

See full
Revenue$193.5M+8.9%
Gross profit$117.2M+20.5%
Operating income$30.9M+42.5%
Net income$14.5M+500%
EPS (diluted)$0.40+471%

Balance sheet

See full
Cash & equivalents$289.6M+147%
Total debt$5.2M-19.5%
Total equity$312.4M+33.3%
Total assets$1.7B+1.3%

Cash flow

See full
Operating cash flow$57.1M+3.1%
CapEx$270.0K-66.2%
Free cash flow$56.8M+4.1%

Valuation

See full
Market cap$1.15B+20.4%
Enterprise value$869.67M+2.5%
P/E15.4×-6.4×
P/S1.5×0.0×

Profitability

See full
Gross margin60.7%+3.0pp
Operating margin23.7%+2.3pp
Net margin9.4%+2.8pp
FCF margin41.4%+10.4pp

Returns & leverage

See full
Return on equity27.4%+8.2pp
Debt / equity0×0.0×
Current ratio1.7×+0.6×

Where this comes from

Reported directly by Collegium Pharmaceutical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Collegium Pharmaceutical, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Collegium Pharmaceutical, Inc.'s symproic — product revenues, net.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Collegium Pharmaceutical, Inc.'s symproic — product revenues, net?
Collegium Pharmaceutical, Inc. (COLL) reported symproic — product revenues, net of $4.19M in Q1 2026.
How has Collegium Pharmaceutical, Inc.'s symproic — product revenues, net changed year-over-year?
Collegium Pharmaceutical, Inc.'s symproic — product revenues, net increased by 49.0% year-over-year, from $2.82M to $4.19M.
What is the long-term trend for Collegium Pharmaceutical, Inc.'s symproic — product revenues, net?
Over 2 years (2022 to 2024), Collegium Pharmaceutical, Inc.'s symproic — product revenues, net has grown at a 11.0% compound annual growth rate (CAGR), from $12.27M to $15.1M.
What does symproic — product revenues, net mean?
Represents the total net revenue generated from the sale of the Symproic product line after accounting for returns, rebates, and discounts. This metric is a key indicator of the product's market adoption and commercial performance within the company's specialty pharmaceutical portfolio.